Abstract
Mycobacteria have a unique cell wall, which is rich in drug targets. The cell wall core consists of a peptidoglycan layer, a mycolic acid layer, and an arabinogalactan polysaccharide connecting them. The detailed structure of the cell wall core is largely, although not completely, understood and will be presented. The biosynthetic pathways of all three components reveal significant drug targets that are the basis of present drugs and/or have potential for new drugs. These pathways will be reviewed and include enzymes involved in polyisoprene biosynthesis, soluble arabinogalactan precursor production, arabinogalactan polymerization, fatty acid synthesis, mycolate maturation, and soluble peptidoglycan precursor formation. Information relevant to targeting all these enzymes will be presented in tabular form. Selected enzymes will then be discussed in more detail. It is thus hoped this chapter will aid in the selection of targets for new drugs to combat tuberculosis.
Keywords: Tuberculosis, drug discovery, cell wall, arabinogalactan, mycolic acids, peptidoglycan, drug target
Infectious Disorders - Drug Targets
Title: Targeting the Formation of the Cell Wall Core of M. tuberculosis
Volume: 7 Issue: 2
Author(s): Clifton E. Barry, Dean C. Crick and Michael R. McNeil
Affiliation:
Keywords: Tuberculosis, drug discovery, cell wall, arabinogalactan, mycolic acids, peptidoglycan, drug target
Abstract: Mycobacteria have a unique cell wall, which is rich in drug targets. The cell wall core consists of a peptidoglycan layer, a mycolic acid layer, and an arabinogalactan polysaccharide connecting them. The detailed structure of the cell wall core is largely, although not completely, understood and will be presented. The biosynthetic pathways of all three components reveal significant drug targets that are the basis of present drugs and/or have potential for new drugs. These pathways will be reviewed and include enzymes involved in polyisoprene biosynthesis, soluble arabinogalactan precursor production, arabinogalactan polymerization, fatty acid synthesis, mycolate maturation, and soluble peptidoglycan precursor formation. Information relevant to targeting all these enzymes will be presented in tabular form. Selected enzymes will then be discussed in more detail. It is thus hoped this chapter will aid in the selection of targets for new drugs to combat tuberculosis.
Export Options
About this article
Cite this article as:
Clifton E. Barry , Dean C. Crick and Michael R. McNeil , Targeting the Formation of the Cell Wall Core of M. tuberculosis, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001808
DOI https://dx.doi.org/10.2174/187152607781001808 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-pathogenic Strategies for Fighting Pseudomonas aeruginosa Infections- probiotic Soluble Compounds as Inhibitors of Quorum Sensing Genes Expression
Current Organic Chemistry Immune Mechanisms of Sublingual Immunotherapy and Mycobacterial Adjuvants in the Treatment of Allergic Disease
Current Immunology Reviews (Discontinued) Operational Issues and Barriers to Implementation of Prevention of Mother-to-Child Transmission of HIV (PMTCT) Interventions in Sub- Saharan Africa
Current HIV Research CAPi: Computational Model for Apicoplast Inhibitors Prediction Against Plasmodium Parasite
Current Computer-Aided Drug Design Anti-Bacterial
Current Bioactive Compounds Effective Therapy with the Neuroleptic Thioridazine as an Adjunct to Second Line of Defence Drugs, and the Potential that Thioridazine Offers for New Patents that Cover a Variety of “New Uses”
Recent Patents on Anti-Infective Drug Discovery 2D- and 3D-QSAR Studies of Flavonoids, Biflavones and Chalcones: Antiviral, Antibacterial, Antifungal, and Antimycobacterial Activities
Anti-Infective Agents Synthesis, Antitubercular Activity, Molecular Modeling and Docking Studies of Novel Thiazolidin-4-One Linked Dinitrobenzamide Derivatives
Current Bioactive Compounds Biomedical Devices for Pathogen Detection Using Microfluidic Chips
Current Proteomics Fight Against H1N1 Influenza A Virus: Recent Insights Towards the Development of Druggable Compounds
Current Medicinal Chemistry Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Bilosomes: A Novel Approach to Meet the Challenges in Oral Immunization
Recent Patents on Drug Delivery & Formulation Novel Urea/Thiourea Derivatives of Quinazolin-4(3H)-one: Design, Synthesis, Antimicrobial and Anti-TB Study
Letters in Drug Design & Discovery Xenicane Natural Products: Biological Activity and Total Synthesis
Current Pharmaceutical Design Synthesis and In Vitro Antimicrobial Evaluation of 4-alkyl/aryl-1-(3-phenoxypropionyl)-thiosemicarbazides
Letters in Drug Design & Discovery Inhibition of Efflux of Quinolines as New Therapeutic Strategy in Malaria
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Infective Drug Discovery Bacterial Resistance to Antimicrobial Host Defenses - An Emerging Target for Novel Antiinfective Strategies?
Current Drug Targets Imidazole and Pyrazole: Privileged Scaffolds for Anti-Infective Activity
Mini-Reviews in Organic Chemistry Nanoparticle-Based Diagnosis and Therapy
Current Drug Targets